SCHEDULE: Iroquois Capital Boosts Clearmind Medicine Stake

Iroquois Capital Management, LLC and its principals, Richard Abbe and Kimberly Page, reported significant beneficial ownership in Clearmind Medicine Inc., primarily through warrants.

Summary

• Iroquois Capital Management, LLC, Richard Abbe, and Kimberly Page reported beneficial ownership in Clearmind Medicine Inc. as of September 30, 2025.
• Iroquois Capital Management, LLC beneficially owns 310,990 shares, representing 5.38% of the common stock class.
• Richard Abbe beneficially owns 603,470 shares, representing 9.94% of the common stock class.
• Kimberly Page beneficially owns 310,990 shares, representing 5.38% of the common stock class.
• The reported ownership primarily consists of shares issuable upon the exercise of warrants.
• Warrants are subject to 'Blockers' preventing exercise if beneficial ownership would exceed 9.99% (or 4.99% for certain warrants).
• The percentage of class is based on 5,466,441 common shares outstanding as of September 18, 2025, as reported in the Company's Registration Statement on Form F-1.

Sentiment

Score: 7

Explanation: The disclosure of significant beneficial ownership by Iroquois Capital Management, LLC and its principals, primarily through warrants, suggests a positive long-term view on Clearmind Medicine Inc.'s potential.

Positives

• Significant beneficial ownership by an investment firm (Iroquois Capital Management, LLC) and its principals, indicating confidence in Clearmind Medicine Inc.
• The investment is primarily through warrants, suggesting a long-term bullish view on the company's stock price potential.

Risks

• The 'Blockers' on warrant exercise limit the immediate ability of the reporting persons to increase their voting power beyond 9.99% (or 4.99% for some warrants), potentially restricting their influence.
• The value of the warrants is dependent on the future stock price of Clearmind Medicine Inc.

Future Outlook

na

Industry Context

This filing is a standard disclosure of beneficial ownership by an investment firm and its principals, which is common across various industries when an entity crosses a 5% ownership threshold. It does not provide specific industry-related insights for Clearmind Medicine Inc.

Stakeholder Impact

• Shareholders: The disclosure of significant institutional ownership may instill confidence and potentially attract further investor interest.
• Management: Increased institutional ownership could lead to greater scrutiny or engagement from the reporting persons, though the filing states the securities were not acquired for influencing control.

Key Dates

Recommendation

While the significant beneficial ownership by Iroquois Capital Management and its principals, primarily through warrants, indicates a positive long-term view, this filing alone does not provide sufficient operational or financial details of Clearmind Medicine Inc. to warrant a 'buy' or 'strong buy' recommendation. It primarily signals institutional confidence, which is a positive factor, but a comprehensive investment decision would require further analysis of the company's fundamentals, strategy, and market position. Therefore, a 'hold' is appropriate, pending deeper due diligence.

Keywords

Clearmind Medicine Inc., CMND, Iroquois Capital Management, Richard Abbe, Kimberly Page, beneficial ownership, Schedule 13G, warrants, institutional ownership, SEC filing